News
-
Dec 06, 2017
C3i is attending the 59th ASH Annual Meeting and Exposition next week!
Read MoreC3i will attend the 59th ASH Annual Meeting and Exposition in Atlanta from December 9th to 12th to engage with researchers, clinicians and industry leaders in the Hematology field. François Bettez, our CEO as well as Dr Lambert Busque our CMO, and Dr Denis-Claude Roy ou CSO, will be representing and promoting C3i for its outstanding capacity to help biotech companies and pharmas to achieve their objectives.
-
Dec 04, 2017
C3i is attending the Cell Therapy Manufacturing & Gene Therapy Congress next week!
Read MoreC3i will attend the Cell Therapy Manufacturing & Gene Therapy Congress in Amsterdam from December 5th to 7th to engage with researchers, clinicians and industry leaders in the cGMP manufacturing area. Arnaud will be representing and promoting C3i for its cGMP manufacturing commercial capacity, adapted to the needs of our numerous partners. Get in touch to know […]
-
Nov 13, 2017
C3i is attending the NeoAntigen Summit in Boston!
Read MoreC3i will attend the Neoantigen Summit in Boston from November 14th to 16th to hear about the latest developments in neoantigen discovery and monitoring.
-
Nov 13, 2017
C3i’s Biomarker and Diagnostic unit now offers TCR-beta sequencing services
Read MoreThe Center for Commercialization of Cancer Immunotherapy (C3i) is proud to announce the availability of T cell receptor-beta sequencing services in its Biomarker and Diagnostic unit.
-
Sep 30, 2017
C3i participates to the challenge Cycle for a Cure!
Read MoreThe 6th edition of the Bike Challenge for Cellular Therapy Research at the Maisonneuve-Rosemont Hospital will give you the opportunity to support scientific work that promotes healing.